CD19+CD21low B cells and CD4+CD45RA+CD31+ T cells correlate with first diagnosis of chronic graft-versus-host disease.

[1]  B. Blazar,et al.  Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets. , 2017, The New England journal of medicine.

[2]  H. Greinix,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease , 2015 .

[3]  J. Ritz,et al.  Current issues in chronic graft-versus-host disease. , 2014, Blood.

[4]  S. Roedder,et al.  Biologic markers of chronic GVHD , 2014, Bone Marrow Transplantation.

[5]  T. Braun,et al.  Plasma CXCL9 elevations correlate with chronic GVHD diagnosis. , 2014, Blood.

[6]  G. Dekan,et al.  CD19(+)CD21(low) B cells and patients at risk for NIH-defined chronic graft-versus-host disease with bronchiolitis obliterans syndrome. , 2013, Blood.

[7]  G. Alter,et al.  Decoupling activation and exhaustion of B cells in spontaneous controllers of HIV infection , 2013, AIDS.

[8]  A. Böhm,et al.  Significantly worse survival of patients with NIH-defined chronic graft-versus-host disease and thrombocytopenia or progressive onset type: results of a prospective study , 2012, Leukemia.

[9]  J. Ritz,et al.  Interleukin-2 and regulatory T cells in graft-versus-host disease. , 2011, The New England journal of medicine.

[10]  R. Storb,et al.  Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. , 2011, Blood.

[11]  W. Pickl,et al.  Significant differences in B-cell subpopulations characterize patients with chronic graft-versus-host disease-associated dysgammaglobulinemia. , 2011, Blood.

[12]  J. Ritz,et al.  Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease. , 2011, Blood.

[13]  G. Socié.  Chronic GVHD: B cells come of age. , 2011, Blood.

[14]  D. Hafler,et al.  FOXP3+ regulatory T cells in the human immune system , 2010, Nature Reviews Immunology.

[15]  J. Ritz,et al.  Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. , 2010, The Journal of clinical investigation.

[16]  S. Tangye,et al.  Differential expression of CD21 identifies developmentally and functionally distinct subsets of human transitional B cells. , 2010, Blood.

[17]  Hermann Einsele,et al.  Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective , 2009, Biology of Blood and Marrow Transplantation.

[18]  M. Kouba,et al.  Proportions of immature CD19+CD21- B lymphocytes predict the response to extracorporeal photopheresis in patients with chronic graft-versus-host disease. , 2009, Blood.

[19]  J. Ritz,et al.  Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. , 2009, Blood.

[20]  A. Thiel,et al.  Life after the thymus: CD31+ and CD31- human naive CD4+ T-cell subsets. , 2009, Blood.

[21]  J. Sprent,et al.  Homeostasis of naive and memory T cells. , 2008, Immunity.

[22]  G. Cuvelier,et al.  Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group. , 2008, Blood.

[23]  M. Kouba,et al.  Elevated numbers of immature/transitional CD21- B lymphocytes and deficiency of memory CD27+ B cells identify patients with active chronic graft-versus-host disease. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[24]  J. Phair,et al.  Homeostasis of the Naive CD4+ T Cell Compartment during Aging1 , 2008, The Journal of Immunology.

[25]  R. Zufferey,et al.  Correlation between recent thymic emigrants and CD31+ (PECAM‐1) CD4+ T cells in normal individuals during aging and in lymphopenic children , 2007, European journal of immunology.

[26]  J. Ritz,et al.  High Levels of B-Cell Activating Factor in Patients with Active Chronic Graft-Versus-Host Disease , 2007, Clinical Cancer Research.

[27]  R. Gress,et al.  T cell immune reconstitution following lymphodepletion. , 2007, Seminars in immunology.

[28]  M. Tanimoto,et al.  Donor-derived thymic-dependent T cells cause chronic graft-versus-host disease. , 2007, Blood.

[29]  James Ferrara,et al.  Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[30]  Daniel Wolff,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[31]  A. Cumano,et al.  Numbers of Foxp3-expressing CD4+CD25high T cells do not correlate with the establishment of long-term tolerance after allogeneic stem cell transplantation. , 2005, Experimental hematology.

[32]  M. Pierer,et al.  Post‐thymic in vivo proliferation of naive CD4+ T cells constrains the TCR repertoire in healthy human adults , 2005, European journal of immunology.

[33]  T. Phan,et al.  Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. , 2004, Immunity.

[34]  C. Craddock,et al.  Chronic graft-versus-host disease is associated with increased numbers of peripheral blood CD4+CD25high regulatory T cells. , 2004, Blood.

[35]  Catherine J. Wu,et al.  Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. , 2004, Blood.

[36]  M. Flowers,et al.  Chronic graft-versus-host disease. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[37]  John P Klein,et al.  Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. , 2002, Blood.

[38]  Andreas Radbruch,et al.  Two Subsets of Naive T Helper Cells with Distinct T Cell Receptor Excision Circle Content in Human Adult Peripheral Blood , 2002, The Journal of experimental medicine.

[39]  H. Illges,et al.  Regulation of CD21 expression by DNA methylation and histone deacetylation. , 2001, International immunology.

[40]  R. Collins,et al.  Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation. , 2001, Blood.

[41]  C. Thoburn,et al.  Autoreactive T-Cell subsets in acute and chronic syngeneic graft-versus-host disease. , 2001, Transplantation proceedings.

[42]  J. V. Stone,et al.  Long-Term Survival and Late Deaths after Allogeneic Bone Marrow Transplantation , 1999 .

[43]  J. Tschopp,et al.  BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth , 1999, The Journal of experimental medicine.

[44]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[45]  M. Dehoff,et al.  An intronic silencer regulates B lymphocyte cell- and stage-specific expression of the human complement receptor type 2 (CR2, CD21) gene. , 1998, Journal of immunology.

[46]  V. M. Holers,et al.  Mouse complement receptors type 1 (CR1;CD35) and type 2 (CR2;CD21): expression on normal B cell subpopulations and decreased levels during the development of autoimmunity in MRL/lpr mice. , 1997, Journal of immunology.

[47]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[48]  D. Fearon,et al.  Synergistic interaction between complement receptor type 2 and membrane IgM on B lymphocytes. , 1988, Journal of immunology.

[49]  P. Schur,et al.  Decreased expression of the C3b/C4b receptor (CR1) and the C3d receptor (CR2) on B lymphocytes and of CR1 on neutrophils of patients with systemic lupus erythematosus. , 1986, Arthritis and rheumatism.

[50]  K. Sullivan,et al.  Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. , 1980, The American journal of medicine.

[51]  C. Dziuban,et al.  When is a correlation matrix appropriate for factor analysis? Some decision rules. , 1974 .

[52]  H. Kaiser.  A second generation little jiffy , 1970 .

[53]  J. G. Cragg,et al.  The Demand for Automobiles , 1970 .

[54]  J. Ritz,et al.  Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. , 2012, Blood.

[55]  K. Safranow,et al.  CD 4 + CD 25 high regulatory T cells and CD 4 + CD 69 + T cells in peripheral blood of patients with cutaneous lupus erythematosus , 2009 .

[56]  K. Schultz.  Chronic Graft versus Host Disease: Interdisciplinary Management: Pathophysiology of Chronic Graft versus Host Disease , 2009 .

[57]  M. Turner,et al.  National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[58]  J. V. Stone,et al.  Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. , 1999, The New England journal of medicine.

[59]  O. Majdic,et al.  Phenotype of human T cells expressing CD31, a molecule of the immunoglobulin supergene family. , 1992, Immunology.